{
  "abstract": "Tumor hypersialylation drives immunosuppression and limits immunotherapy efficacy by shielding tumor cells and engaging inhibitory immune receptors. Here, we engineered Escherichia coli Nissle 1917 (EcN{Delta}pgi-SAS) as a metabolically confined \"desialylation catalyst\" to remodel the tumor microenvironment. This strain combines HER2-directed adhesion, hypoxia-inducible surface sialidase display for targeted glycan cleavage, and sialic acid catabolism to prevent glycolytic recycling. Critically, disrupting glucose metabolism ({Delta}pgi) restricts bacterial proliferation to sialic acid-rich tumor microenvironment, significantly enhancing biosafety. In mice, EcN{Delta}pgi-SAS colonized tumors and effectively desialylated tumor cells, synergizing with anti-PD-L1 to suppress growth of immunologically \"cold\" tumors. Mechanistically, desialylation reversed immunosuppression by broadly enhancing antitumor immunity. Orally administered EcN{Delta}pgi-SAS substantially inhibited colorectal carcinogenesis, repaired epithelial barrier integrity by restoring tight junctions, and prevented adenoma formation. This integrated strategy establishes a clinically translatable platform for reversing immunosuppression in solid tumors.",
  "abstract_shown": true,
  "affiliations": [
    "Sun Yat-sen University"
  ],
  "article_type": "New results",
  "arxiv": null,
  "author_total": 7,
  "authors": [
    {
      "name": "J. Wang"
    },
    {
      "name": "J. Wang"
    },
    {
      "name": "T. OuYang"
    },
    {
      "name": "B. Shi"
    },
    {
      "name": "H. Meng"
    },
    {
      "name": "Z.-W. Mao"
    },
    {
      "affs": [
        0
      ],
      "name": "W. Xia"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/bq734gb6hashh.bib",
  "cited_by": 0,
  "doi": "10.64898/2026.10.04.756258",
  "fulltext_url": "https://www.biorxiv.org/content/10.64898/2026.10.04.756258v1.full",
  "id": "bq734gb6hashh",
  "issns": [],
  "landing_url": "https://www.biorxiv.org/content/10.64898/2026.10.04.756258v1",
  "language": null,
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "biorxiv",
      "synthetic biology"
    ],
    [
      "openalex",
      "1305|Cancer Research and Treatments"
    ]
  ],
  "openalex": "W7220663212",
  "pdf_url": "https://www.biorxiv.org/content/10.64898/2026.10.04.756258v1.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-04",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/bq734gb6hashh.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:26:11Z",
      "native_id": "10.64898/2026.10.04.756258",
      "source": "biorxiv",
      "url": "https://www.biorxiv.org/content/10.64898/2026.10.04.756258v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "biorxiv:synthetic biology",
      "subfield": "systems-synthetic"
    }
  ],
  "title": "Targeted tumor desialylation by engineered probiotic reprograms the tumor microenvironment to potentiate immunotherapy",
  "title_text": "Targeted tumor desialylation by engineered probiotic reprograms the tumor microenvironment to potentiate immunotherapy",
  "type": "preprint",
  "updated_at": "2026-10-30T12:26:11Z",
  "url": "https://research.draconitic.com/paper/bq734gb6hashh",
  "venue": "bioRxiv",
  "versions": []
}